Business
CytoSorbents Announces Approval of CytoSorb® in Korea in Collaboration with Partner Fresenius Medical Care
CytoSorb now commercially available in Korea - one of the leading economies in Asia - to treat cytokine storm and other illnesses in critically-ill and
About this update from Cytosorbents Corporation
[{"type":"text","content":"CytoSorb now commercially available in Korea - one of the leading economies in Asia - to treat cytokine storm and other illnesses in critically-ill and cardiac surgery patients\n\n\nMONMOUTH JUNCTION, N.J., Jan. 19, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients around the world, announces that the Korean Ministry of Food and Drug Safety (KMFDS) has approved CytoSorb for all equivalent European Union (E.U.) approved indications, including the reduction of cytokine storm, the reduction of bilirubin in liver disease, the reduction of myoglobin in trauma, and the removal of ticagrelor and rivaroxaban during urgent or emergent cardiothoracic surgery.\n\n \n \n \n \n \n \n\n \nCytoSorbents (NASDAQ:CTSO) Announces Korean Approval of CytoSorb, a Treatment of Deadly Cytokine Storm and InflammationMs. Clare Kim, Managing Director of Fresenius Medical Care Korea commented, \"In Korea, the sepsis mortality rate and incidence have increased steadily and remains a major problem in critical care. Under these circumstances, we are pleased to introduce the cytokine adsorber, CytoSorb, to healthcare professionals and patients in Korea. Fresenius Medical Care Korea remains committed to having a positive impact on the care of severely ill patients with CytoSorb.\"\nMr. Vincent Capponi, President and Chief Operating Officer of CytoSorbents, stated, \"We are pleased to have successfully achieved approval of CytoSorb in Korea, in cooperation with our partner Fresenius Medical Care. This was the culmination of a nearly 2-year process that included an on-site audit by the KMFDS and the preparation of a full technical dossier specific to Korea's regulatory requirements. With a world-class medical system serving a population of nearly 52 million people, the Republic of Korea is ranked as one of the leading healthcare systems in the world by the Legatum Institute. Physicians in Korea will now have the opportunity to treat patients with CytoSorb as a leading therapy to fight cytokine storm in many life-threatening conditions such as sepsis, COVID-19, and many others.\"\nMr. Capponi continued, \"We are excited to expand the global footprint of CytoSorb, now in a total of 6...